The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Stock and Other Ownership Interests - Merck
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
 
Gilberto Lopes
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); Merck Sharp & Dohme (Inst)
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
 
Iveta Kudaba
No Relationships to Disclose
 
Dariusz Kowalski
No Relationships to Disclose
 
Byoung Chul Cho
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis
Research Funding - AstraZeneca; Bayer; Novartis; Yuhan
 
Gilberto Castro
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Merck Sharp & Dohme; Pfizer; Roche; Teva
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Vichien Srimuninnimit
No Relationships to Disclose
 
Igor Bondarenko
No Relationships to Disclose
 
Kaoru Kubota
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Sumitomo Dainippon; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Gregory M. Lubiniecki
No Relationships to Disclose
 
Jin Zhang
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Debra A. Kush
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Stock and Other Ownership Interests - Cirina; Sanomics Limited
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Taiho Pharmaceutical (Inst)